Literature DB >> 27427464

Induction of antitoxin responses in Clostridium-difficile-infected patients compared to healthy blood donors.

Alice von Eichel-Streiber1, Wonbeom Paik2, Katherine Knight2, Karina Gisch3, Karolina Nadjafi3, Christine Decker3, Oliver Bosnjak4, Adam Cheknis5, Stuart Johnson6, Christoph von Eichel-Streiber7.   

Abstract

According to the literature Clostridium difficile antitoxins are present in up to 66% of humans. In a survey of ∼400 plasma samples from healthy blood donors we found that less than 6% were positive for anti-TcdA or anti-TcdB antitoxins. Using the same standard immunoassay protocol, we looked for IgG and IgA antitoxins in the blood and stool samples from 25 patients with C. difficile infection (CDI). Some patients with CDI had no antitoxin detected at all, while others had high levels of specific IgG- and IgA-antitoxins against both TcdA and TcdB in blood and IgA-anti-TcdA and -anti-TcdB antibodies in stool. Systemic responses to TcdB and mucosal responses to TcdA predominated. Among patients infected with the NAP1/027/BI strain, systemic IgG-anti-TcdB responses were particularly elevated. In contrast, patients infected with non-027 strains had more elevated mucosal IgA-anti-TcdA responses. Furthermore, high titer sera did not correlate with high neutralizing potential. We hypothesize that paradoxical killing of primed B-cells by antibody-mediated endosomal uptake of the Large Clostridial Toxins, TcdA and TcdB leads to clonal elimination of the fittest B-cells. If this hypothesis is confirmed, immune suppression rather than protective humoral immunity might be the consequence in some patients infected with toxigenic C. difficile.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Anti-Toxin antibodies; Antigen presenting cell; C. difficile infection (CDI); Clostridium difficile; Recurrent CDI; Toxin A; Toxin B. clonal elimination

Mesh:

Substances:

Year:  2016        PMID: 27427464     DOI: 10.1016/j.anaerobe.2016.07.001

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  3 in total

1.  Oral Immunotherapy With Human Secretory Immunoglobulin A Improves Survival in the Hamster Model of Clostridioides difficile Infection.

Authors:  Estelle F Chiari; William Weiss; Michael R Simon; Stephan T Kiessig; Mark Pulse; Stephen C Brown; Hanne R Gerding; Maurice Mandago; Karina Gisch; Christoph von Eichel-Streiber
Journal:  J Infect Dis       Date:  2021-10-28       Impact factor: 5.226

2.  Antigen-Specific vs. Neutralizing Antibodies Against Conditioned Media of Patients With Clostridioides difficile Infection: A Prospective Exploratory Study.

Authors:  Sophie Roth; Philipp Jung; James Boone; Alexander Mellmann; Anna Nimmesgern; Sören L Becker; Fabian K Berger; Lutz von Müller
Journal:  Front Microbiol       Date:  2022-02-24       Impact factor: 5.640

3.  High prevalence of subclass-specific binding and neutralizing antibodies against Clostridium difficile toxins in adult cystic fibrosis sera: possible mode of immunoprotection against symptomatic C. difficile infection.

Authors:  Tanya M Monaghan; Ola H Negm; Brendon MacKenzie; Mohamed R Hamed; Clifford C Shone; David P Humphreys; K Ravi Acharya; Mark H Wilcox
Journal:  Clin Exp Gastroenterol       Date:  2017-07-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.